Barbara Finck

Part of Comera Life Sciences Holdings, Inc., Comera Life Sciences, Inc. is a private company that has developed a technology platform to transform the formulation of biotherapeutics for the benefit of patients. The company is based in Woburn, MA. Reform Biologics, a subsidiary of Comera Life Sciences, offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics. The company's patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for biopharmaceutical partners. Reform Biologics creates gentler therapies for fragile patients, including pediatric patients, by using their proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. The company's goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. The company was founded by David S. Soane, Zachariah Jonasson, and Jeffrey S Hackman has been the CEO of the company since 2021. Comera Life Sciences was acquired by OTR Acquisition Corp. on May 20, 2022 for $156.08 million.

NKT Therapeutics, Inc. operates as a biotechnology company. It focuses on developing therapeutics based on unique immune cells called natural killer NKT cells. The company was founded by Alem Truneh, S. Brian Wilson, Mark Exley, Steve K. Balk, and Mark A. Tepper on November 20, 2008 and is headquartered in Waltham, MA.

Osprey Pharmaceuticals Ltd. develops a series of proprietary therapeutic drugs. Osprey Pharmaceuticals is developing a unique family of therapeutic proteins capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The Company's patented Leukocyte Population Modulators (LPMs) selectively and systematically remove these disease-related leukocytes by targeting the chemokine system a complex network of small proteins and their receptors that regulate the movement and activity of leukocytes. The Company's lead compound is in early clinical development for the treatment of diseases associated with chronic inflammation. Osprey also has a portfolio of preclinical LPMs that target a variety of diseases including inflammatory and immunological disorders, oncology, and cardiovascular disease. Osprey Pharmaceuticals was founded in 1997 and is located in Saint-Laurent, Canada.

Osprey Pharmaceuticals USA, Inc. develops protein therapeutics. The firm provides products for the treatment of inflammatory and autoimmune conditions. The company was founded in 2008 and is headquartered in San Francisco, CA

Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.

EOS Biotechnology, Inc. develops therapeutic and diagnostic drugs. The company was founded by Herbert L. Heyneker, John Lowe, David H. Mack, David W. Martin, Richard Murray, and Stephen W. Weiss and is headquartered in Fermont, California.